5-氨基-3,4-二甲基-噻吩并[2,3-C]哒嗪-6-羧酸4-三氟甲磺酰基-苄基酰胺 | 1451993-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-3,4-二甲基-噻吩并[2,3-C]哒嗪-6-羧酸4-三氟甲磺酰基-苄基酰胺
• 英文名称: VU0467154
• 英文别名: 5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide；5-Amino-3,4-dimethyl-N-[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl]thieno[2,3-c]pyridazine-6-carboxamide；5-amino-3,4-dimethyl-N-[[4-(trifluoromethylsulfonyl)phenyl]methyl]thieno[2,3-c]pyridazine-6-carboxamide
• CAS: 1451993-15-9
• 化学式: C₁₇H₁₅F₃N₄O₃S₂
• 分子量: 444.458
• InChiKey: UDSFKIFLJPECRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-chloro-5,6-dimethylpyridazine-4-carbonitrile 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.58h， 生成 5-氨基-3,4-二甲基-噻吩并[2,3-C]哒嗪-6-羧酸4-三氟甲磺酰基-苄基酰胺
  参考文献：
  名称：

  Selective Activation of M₄ Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

  摘要：

  Positive allosteric modulators (PAMs) of the M-4 muscarinic acetylcholine receptor (mAChR) represent a novel approach for the treatment of psychotic symptoms associated with schizophrenia and other neuropsychiatric disorders. We recently reported that the selective M-4 PAM VU0152100 produced an antipsychotic drug-like profile in rodents after amphetamine challenge. Previous studies suggest that enhanced cholinergic activity may also improve cognitive function and reverse deficits observed with reduced signaling through the N-methyl-D-aspartate subtype of the glutamate receptor (NMDAR) in the central nervous system. Prior to this study, the M-1 mAChR subtype was viewed as the primary candidate for these actions relative to the other mAChR subtypes. Here we describe the discovery of a novel M-4 PAM, VU0467154, with enhanced in vitro potency and improved pharmacokinetic properties relative to other M-4 PAMs, enabling a more extensive characterization of M-4 actions in rodent models. We used VU0467154 to test the hypothesis that selective potentiation of M-4 receptor signaling could ameliorate the behavioral, cognitive, and neurochemical impairments induced by the noncompetitive NMDAR antagonist MK-801. VU0467154 produced a robust dose-dependent reversal of MK-801-induced hyperlocomotion and deficits in preclinical models of associative learning and memory functions, including the touchscreen pairwise visual discrimination task in wild-type mice, but failed to reverse these stimulant-induced deficits in M-4 KO mice. VU0467154 also enhanced the acquisition of both contextual and cue-mediated fear conditioning when administered alone in wild-type mice. These novel findings suggest that M-4 PAMs may provide a strategy for addressing the more complex affective and cognitive disruptions associated with schizophrenia and other neuropsychiatric disorders.

  DOI：

  10.1021/cn500128b

文献信息

• [EN] SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4<br/>[FR] ANALOGUES DE 5-AMINOTHIÉNO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE SUBSTITUÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M4
  申请人：UNIV VANDERBILT

  公开号：WO2013126856A1

  公开（公告）日：2013-08-29

  In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6- carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的5-氨基噻吩[2,3-c]吡啶嗪-6-羧酰胺类似物，其衍生物和相关化合物，这些化合物可用作肌胆碱受体M4（mAChR M4）的正向变构调节剂；制备这些化合物的合成方法；包括这些化合物的药物组合物；以及使用这些化合物和组合物治疗与肌胆碱受体功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。
• SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
  申请人：VANDERBILT UNIVERSITY

  公开号：US20150018309A1

  公开（公告）日：2015-01-15

  In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及取代的5-氨基噻吩[2,3-c]吡嗪-6-羧酰胺类似物、其衍生物和相关化合物，其作为肌动蛋白乙酰胆碱受体M4(mAChR M4)的正向变构调节剂具有用途；制备该化合物的合成方法；包括该化合物的药物组合物；以及使用该化合物和组合物治疗与肌动蛋白乙酰胆碱受体功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• Positive allosteric modulators of the muscarinic acetylcholine receptor M4
  申请人：Vanderbilt University

  公开号：US10736898B2

  公开（公告）日：2020-08-11

  Disclosed herein are tricyclic compounds, including thieno[2,3-d:4,5-d′]dipyrimidin-4-amine and pyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

  本文公开了三环化合物，包括噻吩并[2,3-d:4,5-d′]二嘧啶-4-胺和吡啶并[4′,3′:4,5]噻吩并[2,3-d]嘧啶-8-胺化合物，它们可用作毒蕈碱乙酰胆碱受体 M4（mAChR M4）的正异位调节剂。本文还公开了制造这些化合物的方法、包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗与毒蕈碱乙酰胆碱受体功能障碍相关的神经和精神疾病的方法。
• US9493481B2
  申请人：——

  公开号：US9493481B2

  公开（公告）日：2016-11-15
• US9868746B2
  申请人：——

  公开号：US9868746B2

  公开（公告）日：2018-01-16